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Several growth factors (GFs) have been implicated
in long-term memory (LTM), but no single GF can
support all of the plastic changes that occur during
memory formation. Because GFs engage highly
convergent signaling cascades that often mediate
similar functional outcomes, the relative contribution
of any particular GF to LTM is difficult to ascertain. To
explore this question, we determined the unique
contribution of distinct GF families (signaling via
TrkB and TGF-br-II) to LTM formation in Aplysia.
We demonstrate that TrkB and TGF-br-II signaling
are differentially recruited during two-trial training in
both time (by trial 1 or 2, respectively) and space (in
distinct subcellular compartments). These GFs inde-
pendently regulate MAPK activation and synergisti-
cally regulate gene expression. We also show that
trial 1 TrkB and trial 2 TGF-br-II signaling are required
for LTM formation. These data support the view that
GFs engaged in LTM formation are interactive com-
ponents of a complex molecular network.
INTRODUCTION
Beginning with the pioneering discoveries of Levi-Montalcini,
Cohen, and colleagues (Cohen et al., 1954), it is now appreciated
that growth factors (GFs) are secreted molecules that bind
membrane-associated extracellular receptors, thereby acti-
vating intracellular signaling cascades that ultimately mediate
developmental plasticity. In recent years, it has also become
clear that many of the GFs engaged during development are
re-engaged in the adult to support neuronal plasticity involved
in memory formation.
Memory can exist in a wide range of temporal domains that
can be distinguished by the molecular mechanisms engaged in
their induction and maintenance. For example, short-termmem-
ory (STM) is mediated by post-translational modifications and
lasts minutes to hours, whereas long-term memory (LTM) re-
quires both translation and transcription and can last for several
days or longer (Bailey et al., 1996; Castellucci et al., 1989).
Intriguingly, while a variety of GFs have been implicated in1228 Neuron 86, 1228–1239, June 3, 2015 ª2015 Elsevier Inc.learning and memory processes, no individual GF can, by itself,
support all of the plastic changes that occur during memory for-
mation (Kopec and Carew, 2013). Moreover, there is consider-
able overlap in the roles different GFs play as critical mediators
of plasticity, and their effects are exerted by engaging highly
convergentmolecular signaling cascades (Huang andReichardt,
2003; Massague´, 2000). Therefore, the relative contribution of
each individual GF to LTM formation is difficult to determine.
Aplysia californica is a powerful model system for studying the
molecular mechanisms underlying memory formation (Kandel,
2001). The defensive withdrawal reflexes are mediated in large
measure by sensory neuron (SN)-motor neuron (MN) circuits
(Marinesco et al., 2006; Philips et al., 2011; Sutton et al., 2001;
Walters et al., 1983). LTM for sensitization of the withdrawal re-
flexes, or its underlying cellular correlate, long-term facilitation
(LTF) of SN-MN synapses, can be studied by delivering behav-
ioral training with tail shocks (TSs) or analog training in dissected
ganglion preparations with tail nerve shocks (TNSs). Serotonin
(5HT) is released within the SN-MN circuits during training (Ma-
rinesco and Carew, 2002; Marinesco et al., 2006; Philips et al.,
2011), which induces mitogen-activated protein kinase (MAPK)
activation and gene expression, both of which are required for
LTM formation (Philips et al., 2007, 2013b; Sharma et al., 2003;
Sutton et al., 2001). In addition, LTM, LTF, and MAPK activation
in Aplysia requires signaling from two distinct GF families: tropo-
myosin-related kinase B (TrkB) signaling, a tyrosine kinase that is
the high-affinity receptor for brain derived neurotrophic factor
(BDNF), and transforming growth factor b receptor II (TGF-br-II)
signaling, a serine-threonine kinase that is the receptor for
TGF-b ligands (Chin et al., 2002; Kassabov et al., 2013; Sharma
et al., 2006; Zhang et al., 1997). Furthermore, incubation of
pleural-pedal ganglia or SN-MN co-cultures with mammalian
GF ligands (BDNF and TGF-b) promotes MAPK activation, syn-
aptic strengthening, and LTM (Chin et al., 2002, 2006; Purcell
et al., 2003; Zhang et al., 1997). Collectively, these data indicate
the existence of endogenous Trk and TGF-b GF signaling cas-
cades and their recruitment during memory formation.
As in other systems, the pattern of training trials is of critical
importance for LTM formation in Aplysia (Philips et al., 2013a).
For example, we found that a novel two-trial training pattern con-
sisting of two TSs spaced by 45 min results in LTM for sensitiza-
tion of the withdrawal reflexes (Philips et al., 2007, 2013b). The
temporal distance between the two trials in this training pattern
is highly advantageous, since it permits the analysis of the contri-
bution ofmolecular signaling recruited by each individual training
Figure 1. Trial 1 Recruits TrkB but Not TGF-
br-II Signaling for Early- but Not Late-Phase
MAPK Activation
(A1) Experimental paradigm. Dissected ganglia are
incubated with GF chimera (gray) or vehicle (white)
10 min prior to trial 1 (time 0:00, red arrow) until
SN somata are collected at 0:45 min (vertical black
bar).
(A2) Blocking TrkB signaling during trial 1 signifi-
cantly disrupts early phase MAPK activation. P,
phospho-specificMAPK; T, total MAPK; C, control
ganglia; E, experimental ganglia.
(A3) Blocking TGF-br-II signaling during trial 1 does
not disrupt early-phase MAPK activation.
(B1) Ganglia are incubated with drug 10 min prior
to trial 1 (0:00). Chimera/vehicle is washed out with
ASW (blue) 5 min prior to trial 2 (0:45), and SN
somata are collected 1 hr post-training (1:45).
(B2) Blocking TrkB signaling during trial 1 does not
disrupt late-phase MAPK activation.
(B3) Blocking TGF-br signaling during trial 1 does
not disrupt late-phase MAPK activation. Example
western blots are displayed below the histograms.
In this and all subsequent figures, data are displayed as median ± IQR, within-group statistics are displayed above histogram bars, and between-
group statistics are displayed above the histograms being compared. *p < 0.05, **p < 0.01; n = 6–10.trial to LTM formation. Moreover, measurement of critical molec-
ular signaling (e.g., MAPK activation and gene expression) as a
proxy for LTM formation provides additional tools with which
to assess the regulation of individual molecular cascades com-
mon to bothGF families. Thus, in the present paper, to determine
the distinct contributions of different GF families to LTM forma-
tion, we asked whether and how TrkB and TGF-br-II signaling
uniquely contribute to MAPK activation, gene expression, and
LTM formation induced by two-trial training. We found that trial
1 recruits synaptic TrkB signaling, while trial 2 recruits somatic
TGF-br-II signaling. Furthermore, we found that these GF fam-
ilies act independently to regulate discrete temporal phases of
MAPK activation and synergistically to regulate mRNA levels of
the transcription factor apc/ebp. Finally, these molecular obser-
vations gave rise to specific behavioral predictions for LTM for-
mation. Trial 1 TrkB signaling and trial 2 TGF-br-II signaling
should be essential for LTM. Both of these predictions were
confirmed by examining the tail-elicited siphon withdrawal
reflex.
RESULTS
Trial 1 Recruits TrkB Signaling for Early-Phase MAPK
Activation
In response to sensitizing stimuli, MAPK activation in SN somata
occurs in two distinct phases: during training and after training. A
single training trial induces a transient early phase of MAPK acti-
vation in SN somata at 45 min that, in the absence of additional
training trials, declines back to baseline by 60 min (Philips et al.,
2007; 2013b). However, following repeated-trial training permis-
sive for the induction of LTM, a persistent late phase of MAPK
activation is generated in SN somata from 1–3 hr after training
(Sharma et al., 2003; Ye et al., 2012). Importantly, both phases
of MAPK activation are required for LTM formation (Philips
et al., 2013b; J. Shobe et al., 2005, Soc. Neurosci., abstract).As a first step in characterizing the role of distinct GF families
during LTM formation, we examined the necessity for TrkB and
TGF-br-II signaling upstream of the early and late phases of
MAPK activation.
We first askedwhether trial 1 of two-trial analog training (TNSs)
recruits GF signaling required for either phase of MAPK activa-
tion. To block GF signaling, we utilized TrkB and TGF-br-II chi-
meras, which sequester endogenous GF ligands and, thereby,
inhibit GF signaling. These chimeras have been used previously
to study GF signaling inAplysia (Sharma et al., 2006; Zhang et al.,
1997). Trial 1 was delivered to dissected ganglion preparations in
the presence of GF chimeras (TrkB-Fc chimera and TGF-br-II-Fc
chimera, R&D Systems, 5mg/ml) or vehicle (0.1% BSA in PBS),
and SN somata were collected at 45min (Figure 1A1). Consistent
with previous reports (Philips et al., 2007; 2013b), there was sig-
nificant early-phase MAPK activation at 45 min in the TrkB-Fc
vehicle (Figure 1A2; median ± interquartile range (IQR),
133.0% ± 63.6%; Wilcoxon matched-pairs signed rank (within
group), W = 24; p < 0.05; n = 7) and TGF-br-II-Fc vehicle (Fig-
ure 1A3; 133.3%± 46.2%,W = 34, p < 0.05; n = 7) groups relative
to within-animal control levels (see Experimental Procedures).
Moreover, this early-phase MAPK activation was significantly
attenuated by the TrkB-Fc chimera (Figure 1A2; 92.7% ±
34.0%; n = 6; Mann-Whitney U test (between groups), U = 5;
p < 0.05) but was not disrupted by the TGF-br-II-Fc chimera
(Figure 1A3; 147.2% ± 77.4%,W = 34, p < 0.05, n = 8, 1 outlier).
These data indicate that trial 1 induces the release of a TrkB
ligand that activates early-phase MAPK in SN somata, whereas
TGF-br-II signaling is not engaged by trial 1 for early-phase
MAPK activation.
GF Signaling Recruited by Trial 1 Is Not Required for
Late-Phase MAPK Activation
Given the results so far, trial 1 could still engage TGF-br-II
signaling to mediate late-phase MAPK activation. Similarly,Neuron 86, 1228–1239, June 3, 2015 ª2015 Elsevier Inc. 1229
Figure 2. Trial 2 Recruits TGF-br-II but
Not TrkB Signaling for Late-Phase MAPK
Activation
(A1) Trial 1 (0:00) is delivered in the presence of
ASW, and the drug is applied 10 min prior to trial 2
(0:45). SN somata are collected 1 hr post-training
(1:45).
(A2) Blocking TrkB signaling during trial 2 does not
disrupt late-phase MAPK activation.
(A3) Blocking TGF-br-II signaling during trial 2
significantly disrupts late-phase MAPK activation.
*p < 0.05, **p < 0.01; n = 6–9.TrkB signaling initiated by trial 1 could be required for both the
early and late phases of MAPK activation. To explore these pos-
sibilities, we next askedwhether GF signaling initiated by trial 1 is
required for late-phase MAPK activation. Trial 1 was delivered in
the presence of the GF chimera or vehicle, which was washed
out prior to trial 2, and SN somata were collected 1 hr post-
training (Figure 1B1). As expected, groups receiving TrkB-Fc
vehicle (Figure 1B2; 201.7% ± 111.2%, W = 28, p < 0.05, n = 7)
and TGF-br-II-Fc vehicle (Figure 1B3; 141.3% ± 31.4%, W =
28, p < 0.05, n = 7, 1 outlier) exhibited significant late-phase
MAPK activation. Interestingly, both the TrkB-Fc chimera (Fig-
ure 1B2; 181.0% ± 144.2%, W = 32, p < 0.05, n = 8) and TGF-
br-II-Fc chimera (Figure 1B3; 172.9% ± 70.6%, W = 28, p <
0.05, n = 7, 1 outlier) groups also showed significant late-phase
MAPK activation. Taken together, these data suggest that each
phase ofMAPK activation (trial 1-dependent early phase and trial
2-dependent late phase) is independent, since blocking the
early, TrkB-dependent phase has no effect on the subsequent
late phase. Additionally, TGF-br-II signaling, if it is engaged by
trial 1, is not required for either phase of MAPK activation.
Trial 2 Recruits TGF-br-II Signaling for Late-Phase
MAPK Activation
Given that trial 1 engages GF signaling required for early-phase
MAPK activation, we next asked whether trial 2 engages the
same or different GF signaling cascades for late-phase MAPK
activation. Two-trial analog training was administered, with trial
2 delivered in the presence of the GF chimera or vehicle, and
SN somata were collected 1 hr post-training (Figure 2A1). Both
the TrkB-Fc vehicle (Figure 2A2; 176.4% ± 107.6%, W = 26,
p < 0.05, n = 7) and TGF-br-II-Fc vehicle (Figure 2A3; 213.8% ±
95.0%, W = 45, p < 0.01, n = 9) groups showed significant
late-phase MAPK activation. Moreover, the TrkB-Fc chimera,
during trial 2, did not disrupt late-phase MAPK activation (Fig-
ure 2A2; 189.1% ± 71.4%, W = 21, p < 0.05, n = 6). In contrast,
the TGF-br-II-Fc chimera, during trial 2, did disrupt late-phase
MAPK activation (Figure 2A3; 115.8% ± 87.9%, n = 9). A Krus-
kal-Wallis test of drug treatment (TGF-br-II-Fc chimera or vehicle
during trial 1 or during trial 2) indicated a difference among
groups (H = 8.6, degrees of freedom (df) = 3, p < 0.05), and sub-
sequent planned comparisons revealed a significant difference
between the TGF-br-II-Fc chimera and vehicle groups when
the drug was applied during trial 2 (U = 7, p < 0.01). Collectively,
these data indicate that there is a temporal dissociation of GF
family recruitment during two-trial analog training. Trial 1 prefer-
entially engages TrkB signaling to mediate early-phase MAPK1230 Neuron 86, 1228–1239, June 3, 2015 ª2015 Elsevier Inc.activation, whereas trial 2 preferentially engages TGF-br-II
signaling to mediate late-phase MAPK activation.
TrkB Signaling Is Initiated at the Synapse
Having identified a temporal dissociation for the requirement of
different GF families during two-trial analog training, we next
examined the spatial profile for signaling by each GF family
during its unique temporal phase of training using a split-bath
preparation, which permits manipulation of GF signaling in the
SN-MN circuit independently in either a somatic compartment,
containing SN somata, or a synaptic compartment, containing
the SN-MN synapses and MN somata (Sherff and Carew 1999).
First, we asked whether trial 1 TrkB signaling required for early
phase MAPK activation is initiated in the somatic or synaptic
compartment. We found that, when TrkB signaling is blocked
in the somatic compartment, early-phase MAPK activation is
not affected (Figure 3A, left; TrkB-Fc vehicle, 134.4% ± 48.2%,
W = 45, p < 0.01, n = 9, 1 outlier; TrkB-Fc chimera, 128.5% ±
39.0%, W = 36, p < 0.01, n = 8, 1 outlier). However, when TrkB
signaling is blocked in the synaptic compartment, early-phase
MAPK activation is disrupted significantly (Figure 3A, right;
TrkB-Fc vehicle, 147.7% ± 24.7%, W = 26, p < 0.05, n = 7;
TrkB-Fc chimera, 106.2%± 60.9%, n = 6). A Kruskal-Wallis anal-
ysis indicated that there was a difference among groups (H = 8.3,
df = 3, p < 0.05), and subsequent planned comparisons revealed
a significant difference between synaptic TrkB-Fc chimera and
vehicle treatment on early-phase MAPK activation (U = 4, p <
0.05). These data indicate that trial 1 induces the release of a
TrkB ligand at SN-MN synapses, which mediates early-phase
MAPK activation in SN somata. Intriguingly, these data also sug-
gest the requirement of a retrogradely transported intracellular
signal arising from the synapse to regulate somatic molecular
events (see Discussion).
TGF-br-II Signaling Is Initiated at the Soma
We next examined the site of trial 2 TGF-br-II signaling required
for late-phaseMAPK activation in SN somata. In contrast to TrkB
(Figure 3A), blocking TGF-br-II signaling in the synaptic compart-
ment did not disrupt late-phase MAPK activation (Figure 3B,
right; TGF-br-II-Fc vehicle, 145.7% ± 43.7%, W = 21, p < 0.05,
n = 6, 1 outlier; TGF-br-II-Fc chimera: 169.0% ± 60.6%, W =
21, p < 0.05, n = 6). However, blocking TGF-br-II signaling
in the somatic compartment completely blocked late-phase
MAPK activation (Figure 3B, left; TGF-br-II-Fc vehicle,
148.5% ± 55.5%, W = 28, p < 0.05, n = 7, 1 outlier; TGF-br-II-
Fc chimera, 102.2% ± 40.7%, n = 6). A Kruskal-Wallis analysis
Figure 3. Spatial Dissociation of GF
Engagement: TrkB Signaling Is Initiated at
the Synapse, whereas TGF-br-II Signaling
Is Initiated at the Soma
(A) To determine where GF signaling is initiated
(soma or synapse), a barrier was built between the
SN somata and SN-MN synapses, and drug was
applied to one compartment. The critical phase of
MAPK activation shown to be dependent upon
each GF family is used as a readout (Figures 1
and 2; early phase requires TrkB signaling, and late
phase requires TGF-br-II signaling).
(B) Blocking TrkB signaling during trial 1 in the
synaptic but not somatic compartment signifi-
cantly disrupts early-phase MAPK activation.
(C) Blocking TGF-br-II signaling during trial 2 in the
somatic but not synaptic compartment signifi-
cantly disrupts late-phase MAPK activation. *p <
0.05, **p < 0.01; n = 6–9.
(D and E) Receptor localization for GF ligands was
assessed in SN-MN co-cultures stimulated with
control biotinylated protein or biotinylated GF
ligand, followed by avidin-fluorescein to visualize
binding. Confocal images reveal that SNs andMNs
bind both BDNF (D2) and TGFb1 (E2) but not con-
trol protein (D1 and E1). Yellow triangles indicate
the location of cell bodies in the avidin-fluorescein
images.indicated that there was a significant difference among groups
(H = 9.3, df = 3, p < 0.05), and subsequent planned comparisons
revealed a significant difference between somatic TGF-br-II-Fc
chimera and vehicle treatment on late-phase MAPK activation
(U = 5, p < 0.05). These data indicate that trial 2 induces the
release of a TGF-br-II ligand at SN somata. Therefore, our results
reveal a double dissociation in space and time. Trial 1 recruits
TrkB signaling at the synapse, and trial 2 recruits TGF-br-II
signaling at the soma. Interestingly, incubation of SN-MN co-cul-
ture with biotinylated human recombinant TrkB and TGF-br-II li-
gands (BDNF and TGF-b1, respectively) reveals the potential for
human ligands to bind receptors on both SNs and MNs (Figures
3D and 3E). Taken together, these data indicate that although
there may be receptors for both families of GFs on both the
pre- and post-synaptic components of this circuit, their engage-
ment is spatially restricted during two-trial analog training.Neuron 86, 1228–12Both Trial 1 and Trial 2 Increase
apc/ebp mRNA Expression
Thus far, our results demonstrate that
distinct GF families regulate discrete tem-
poral phases of MAPK activation. Since
transcription is uniquely required for
long-term forms of plasticity and mem-
ory (Bailey et al., 1996), we next asked
whether GF-initiated signaling was up-
stream of learning-related gene expres-
sion. We focused our attention on three
genes: Aplysia CCAAT enhancer-binding
protein (ApC/EBP), which is an immediate
early gene and transcription factor (Alber-ini et al., 1994); Aplysia ubiquitin C-terminal hydrolase (ApUCH),
which is an immediate early gene and associates with the pro-
teasome to increase protein degradation (Hegde et al., 1997);
and Aplysia kinesin heavy chain 1 (ApKHC1), which is a compo-
nent of the anterograde motor protein kinesin that transports
cargo proteins and mRNAs from the soma to the synapse
(Puthanveettil et al., 2008). Importantly, all of these genes have
been demonstrated to be regulated by sensitizing stimuli inAply-
sia and are required for LTF (Alberini et al., 1994; Hegde et al.,
1997; Puthanveettil et al., 2008). We first determined when
mRNA expression of these learning-related genes is increased
(by trial 1 and/or by trial 2), and then asked whether GF signaling
is required for increased expression.
SN somata were collected either 45 min after trial 1, 60 min af-
ter trial 1, or 15 min after trial 2. RNA was isolated for cDNA syn-
thesis, and then the expression of apc/ebp, apuch, and apkhc139, June 3, 2015 ª2015 Elsevier Inc. 1231
Figure 4. Both Trial 1 and Trial 2 Increase
apc/ebp mRNA Expression
(A) Trial 1 (0:00) is delivered, and SN somata are
collected at 0:45 min. apc/ebp, but not apuch or
apkhc1 expression, is increased significantly by
trial 1.
(B) SN somata are collected 1 hr (1:00) after trial 1.
apc/ebp expression has returned to baseline 1 hr
after trial 1.
(C) SN somata are collected 15 min after trial 2
(1:00). apc/ebp, but not apuch or apkhc1 expres-
sion, is increased significantly by trial 2.
**p < 0.01, n = 6–10.mRNA levels was analyzed using quantitative PCR (normalized
to the ubiquitous housekeeping gene apgapdh; see Experi-
mental Procedures). Kruskal-Wallis analyses indicated that there
was a significant difference in gene expression 45min after trial 1
(H = 6.9, df = 2, p < 0.05) and 15 min after trial 2 (H = 9.2, df = 2,
p < 0.05) but not 60 min after trial 1 (H = 3.5, df = 2, p = 0.2).
Subsequent planned comparisons revealed that apc/ebp
mRNA expression is increased significantly 45 min after trial 1
(Figure 4A; 1.9 ± 0.9, W = 51, p < 0.01, n = 10) and, in the
absence of trial 2, returns to control levels 60min after trial 1 (Fig-
ures 4B; 1.0 ± 0.5, n = 6), which is in agreement with our prior
work (Philips et al., 2013b). However, when Trial 2 is delivered,
apc/ebp expression is increased significantly at an equivalent
time point (15 min after trial 2; Figure 4C; 1.6 ± 0.6, W = 36,
p < 0.01, n = 8). In contrast, apuch and apkhc1 mRNA levels
were not regulated at any time point assessed (Figure 4). Since
apuch and apkhc1 expression levels have been reported to be
regulated by sensitizing stimuli in Aplysia (Hegde et al., 1997;
Mohamed et al., 2005; Puthanveettil et al., 2008), these data sug-
gest either that apuch and apkhc1 expression is regulated at
different points in time or that different training patterns that
result in the same functional outcome (e.g., LTM or LTF) may re-
cruit distinct gene expression profiles. Taken together, these re-
sults indicate that increased apc/ebp expression is dependent
upon both trial 1 and trial 2.
Trial 1-Dependent apc/ebp Expression Requires TrkB
Signaling during Trial 1
To examine the requirement of GF signaling during trial 1 for trial
1-dependent apc/ebp expression, we performed experiments in
the presence of the GF chimera or vehicle (Figure 5A1). apc/ebp
expression was elevated significantly 45 min after trial 1 in the
presence of TrkB-Fc vehicle (Figure 5A2; 2.1 ± 0.9, W = 28,
p < 0.05, n = 7) and TGF-br-II-Fc vehicle (Figure 5A3; 1.5 ± 1.6,
W = 26, p < 0.05, n = 7). However, trial 1-dependent apc/ebp
expression was disrupted significantly by treatment with the
TrkB-Fc chimera (Figure 5A2; 1.1 ± 0.7, n = 6; U = 3, p < 0.01)
but not the TGF-br-II-Fc chimera (Figure 5A3; 1.7 ± 1.0,
W = 28, p < 0.05, n = 7). apuch and apkhc1 mRNA levels
were analyzed by quantitative PCR (qPCR) in parallel with apc/
ebp (Figure 5) and confirmed the lack of regulation seen in the
initial experiment (Figure 4A). Our results are consistent with
our previous findings (Figure 1) and support the hypothesis
that TrkB signaling is preferentially engaged by trial 1 to regulate
MAPK activation and gene expression.1232 Neuron 86, 1228–1239, June 3, 2015 ª2015 Elsevier Inc.Trial 2-Dependent apc/ebp Expression Requires
TGF-br-II Signaling during Trial 2
We next tested the hypothesis that trial 2 preferentially recruits
TGF-br-II signaling to mediate Trial 2-dependent apc/ebp
expression. Two-trial analog training was administered, with trial
2 delivered in the presence of GF chimera or vehicle, and SN
somata were collected 15 min post-training (Figure 5B1). In the
presence of TrkB-Fc vehicle (Figure 5B2; 1.7 ± 0.4, W = 34,
p < 0.05, n = 8) and TGF-br-II-Fc vehicle (Figure 5B3; 1.5 ± 0.4,
W =28, p < 0.05, n = 7, 1 outlier) during trial 2, apc/ebp expres-
sion was increased significantly 15 min post-training. Trial
2-dependent apc/ebp expression was disrupted by blocking
TGF-br-II signaling during trial 2 (Figure 5B3; 1.0 ± 0.3, n = 8)
but not TrkB signaling during trial 2 (Figure 5B2; 1.5 ± 0.7,
W =26, p < 0.05, n = 7). Furthermore, a Kruskal-Wallis test of
drug treatment (TGF-br-II-Fc chimera or vehicle during trial 1
(Figure 6A3) or during trial 2) indicated a difference among groups
(H = 9.2, df = 3, p < 0.05), and subsequent planned comparisons
revealed a significant difference between TGF-br-II-Fc chimera
and vehicle groups when the drug was applied during trial 2
(U = 6, p < 0.01). Taken together, these data are consistent
with the notion that there are distinct signaling profiles for each
GF family. Trial 1 specifically engages TrkB signaling, and trial
2 specifically engages TGF-br-II signaling to support both
MAPK activation and apc/ebp expression.
Trial 2 TGF-br-II Signaling Prolongs TrkB-Dependent
apc/ebp Expression Established by Trial 1
Since apc/ebp expression is regulated by both TrkB (trial
1-dependent; Figure 5A2) and TGF-br-II signaling (trial 2-depen-
dent; Figure 5B3), we next sought to explore the regulation of the
same transcript by both GF families. There are two general pos-
sibilities that could account for the results shown in Figure 5: trial
1 increases apc/ebp expression, and trial 2 prolongs the expres-
sion of these mRNAs, or trial 1 and trial 2 both independently in-
crease apc/ebp expression. In the former case, if trial 1 increases
apc/ebp expression, which, in turn, is prolonged by trial 2, then
blocking trial 1 TrkB signaling should block trial 2-dependent
apc/ebp expression because there would be no mRNA for trial
2 to prolong. In contrast, if trial 2 independently increases apc/
ebp expression, then blocking trial 1 TrkB signaling should
have no effect on trial 2-dependent apc/ebp expression. Trial 1
was delivered in the presence of the GF chimera or vehicle,
which was washed out prior to trial 2, and SN somata were
collected 15 min post-training (Figure 6A1). Blocking TrkB
Figure 5. Trial 1-Dependent apc/ebp
Expression Requires TrkB Signaling during
Trial 1, and Trial 2-Dependent apc/ebp
Expression Requires TGF-br-II Signaling
during Trial 2
(A1) Ganglia are incubated with drug 20 min prior
to trial 1 (0:00), and SN somata are collected at
0:45 min.
(A2) Blocking TrkB signaling during trial 1
significantly disrupts trial 1-dependent apc/ebp
expression.
(A3) Blocking TGF-br-II signaling during trial 1 does
not disrupt trial 1-dependent apc/ebp expression.
(B1) Trial 1 (0:00) is delivered in the presence of
ASW, and drug is applied 20 min prior to trial 2
(0:45). SN somata are collected 15 min post-
training (1:00).
(B2) Blocking TrkB signaling during trial 2 does not
disrupt trial 2-dependent apc/ebp expression.
(B3) Blocking TGF-br-II signaling during trial 2
significantly disrupts trial 2-dependent apc/ebp
expression.
*p < 0.05, **p < 0.01; n = 6–8.signaling during trial 1 did, in fact, disrupt trial 2-dependent apc/
ebp expression (Figure 6A2; TrkB-Fc vehicle, 1.4 ± 0.5,W =43,
p < 0.01, n = 9; TrkB-Fc chimera, 1.0 ± 0.3, n = 8), while blocking
TGFbr-II signaling during trial 1 had no effect (Figure 6A3; TGF-
br-II-Fc vehicle, 1.3 ± 0.1, W = 26, p < 0.05, n = 7, 1 outlier;
TGF-br-II-Fc chimera, 1.3 ± 0.4, W = 21, p < 0.05, n = 6). A
Kruskal-Wallis test of drug treatment (TrkB-Fc chimera or vehicle
during trial 1 or trial 2) indicated a difference among groups (H =
9.3, df = 3, p < 0.05), and subsequent planned comparisons re-
vealed a significant difference between the TrkB-Fc chimera and
vehicle groups when the drug was applied during trial 1 (U = 10,
p < 0.05). These data therefore support the hypothesis that trial 2
TGF-br-II signaling interacts with the TrkB signaling cascade to
prolong apc/ebp expression established by trial 1.
Trial 1 TrkB Signaling and Trial 2 TGF-br-II Signaling Are
Required for LTM for Sensitization
The molecular observations we obtained so far provide clear
predictions for the role of GFs in the induction of LTM for sensi-
tization in Aplysia. Specifically, our molecular data predict that
TrkB signaling should be recruited by trial 1 for LTM formation,
and TGF-br-II signaling should be recruited by trial 2 for LTM
formation. We directly tested these hypotheses in a final set
of behavioral experiments examining LTM for sensitization of
the defensive tail-elicited siphon withdrawal reflex (T-SWR).
We used the T-SWR semi-intact preparation (Figure 7A; Philips
et al., 2007; Sutton et al., 2001) to manipulate the molecular
environment of the CNS while directly measuring withdrawal
responses (see Experimental Procedures).
To test the hypothesis that TrkB signaling is recruited by trial 1
for LTM formation, we exposed the CNS to the TrkB-Fc chimera
or vehicle during trial 1, which was washed out prior to trial 2. In
the presence of TrkB-Fc vehicle, significant LTM for sensitization
of the T-SWR was observed (Figure 7B; 154.0% ± 68.4%, W =
21, p < 0.05, n = 6). In contrast, the induction of LTM was disrup-
ted significantly when TrkB signaling was blocked during trial 1
(Figure 7B; 103.9% ± 6.5%, n = 6, 1 outlier; U = 0, p < 0.01).To test the hypothesis that TGF-br-II signaling is recruited
by trial 2 for LTM formation, we administered two-trial training
with the CNS exposed to the TGF-br-II chimera or vehicle during
trial 2. In the presence of TGF-br-II-Fc vehicle, significant LTM for
sensitization was induced (Figure 7C; 179.4% ± 59.3%,W = 21,
p < 0.05, n = 6). In contrast, LTM was disrupted significantly
when TGF-br-II signaling was blocked during trial 2 (Figure 7C;
109.4% ± 14.5%, n = 6; U = 3, p < 0.05). These behavioral
data confirm the predictions derived from our molecular obser-
vations and support a general model in which trial 1 recruits
TrkB signaling and trial 2 recruits TGF-br-II signaling to mediate
molecular changes critical for LTM formation.
DISCUSSION
In this paper, we show that GF signaling via TrkB and TGF-br-II
receptors is highly regulated both temporally (during trial 1
versus during trial 2) and spatially (synapse versus soma) in
response to stimuli that induced LTM in Aplysia. Collectively,
our data support the working model shown in Figure 8. We
propose that trial 1 recruits synaptic TrkB signaling to mediate
early-phase MAPK activation and increases in apc/ebp mRNA
expression (Figure 8A). Subsequently, trial 2 recruits somatic
TGF-br-II signaling, which produces two effects. It synergisti-
cally interacts with the molecular cascade established by
TrkB signaling to prolong apc/ebp mRNA expression, and it
independently induces late-phase MAPK activation (Figure 8B).
Furthermore, the molecular network comprised of trial 1 TrkB-
Trial 2 TGF-br-II is required for the induction of LTM for sensiti-
zation of the T-SWR (Figure 7). To our knowledge, these exper-
iments provide the first evidence for the parallel recruitment
of distinct GF families by different training trials during LTM
formation, the engagement of different GF families in distinct
subcellular compartments as a function of training pattern,
and the interaction between specific molecular signaling cas-
cades that have been engaged by distinct GF families during
LTM formation.Neuron 86, 1228–1239, June 3, 2015 ª2015 Elsevier Inc. 1233
Figure 6. Trial 2 TGF-br-II Signaling Pro-
longs apc/ebp Expression Established by
Trial 1 TrkB Signaling
(A1) Ganglia are incubated with drug 20min prior to
trial 1 (0:00), which is washed out with ASW 15min
prior to trial 2. SN somata are collected 15 min
post-training (1:00).
(A2) Blocking TrkB signaling during trial 1
significantly disrupts trial 2-dependent apc/ebp
expression.
(A3) Blocking TGF-br-II during trial 1 does not
disrupt trial 2-dependent apc/ebp expression.
*p < 0.05, **p < 0.01; n = 6–9.Temporal Dissociation of GF Signaling during Memory
Formation
During neuronal development, GF signaling is tightly controlled
in time and space to create a specific, stereotyped neural circuit
(Cohen-Cory et al., 2010; Heerssen and Segal, 2002; Massague´,
2000). Our data are consistent with emerging evidence indi-
cating that similar temporal and spatial regulation of GF signaling
occurs during memory formation (Kopec and Carew, 2013).
Our core observations summarized in Figure 8 raise a signifi-
cant question. Why does Trial 1 preferentially recruit TrkB
signaling at the synapse, while trial 2 preferentially recruits
TGF-br-II signaling at the soma? The mRNA for BDNF (the
mammalian ligand for TrkB) has been shown to be targeted to
and stored at synapses and is rapidly translated and released
in response to activity-dependent stimuli (Kuczewski et al.,
2009; Tongiorgi, 2008). BDNF can therefore be considered the
‘‘first responder’’ to learning-related stimuli and, as our data
demonstrate, is poised to prime a neural circuit for information
storage (Figure 8A). Consistent with this notion, in studies exam-
ining memory formation, BDNF-TrkB signaling is often reported
to be required either during or shortly after behavioral training
(Kuczewski et al., 2009; Tongiorgi, 2008). That said, there is
also clear evidence for later phases of BDNF signaling at time
points after training (Bambah-Mukku et al., 2014; Bekinschtein
et al., 2007, 2008) to support memory persistence.
The preferential engagement of TGF-br-II signaling by trial 2
(Figure 8B) supports the view that the molecular environment
established by trial 1 alone may not be sufficient to support
TGF-br-II signaling. There are at least three possibilities that
might account for this observation: there is no TGF-br-II ligand
released by trial 1, there are not sufficient receptors to transduce
signaling by TGF-br-II ligands released during trial 1, and there is
a limiting factor in the TGF-b-TGF-br-II signaling cascade that is
not active during trial 1. To distinguish among these possibilities,
in future studies it will be critical to determine whether protein
and mRNA levels of TGF-br-II and its ligand are regulated by
individual training trials during memory formation. Previous evi-
dence showed that TGF-b can be released in a pro-form that
requires extracellular cleavage by metalloproteases and/or in-
tegrins to signal via its receptor (Annes et al., 2003). Therefore,
the protein or activity levels of proteases could orchestrate the
temporal profile in which TGFb signaling occurs. Liu and col-
leagues (1997) have characterized an Aplysia homolog of the
Drosophila metalloprotease Tolloid. Interestingly, Tolloid mRNA
is upregulated by sensitizing stimuli, indicating that the induction1234 Neuron 86, 1228–1239, June 3, 2015 ª2015 Elsevier Inc.and translation of Tolloid could be a prerequisite to TGF-br-II
signaling, which may, in part, explain the delayed engagement
of this GF family.
The data in this paper indicate that GF signaling in temporally
distinct profiles mediates discrete temporal phases of MAPK
activation induced by learning-related stimuli (Figures 1 and 2).
In a wide range of preparations, MAPK is activated by
learning-related stimuli both during and after training (Sweatt,
2004). However, whether there are mechanistically distinct
phases of activation is not well understood. Our results indicate
that, in Aplysia SN somata, there are at least two independent
phases of MAPK activation: an early phase that can be identified
during the inter-trial training interval and a late (persistent) phase
that is evident only after the second trial. The induction of persis-
tent MAPK activation after training as well as a requirement for
MAPK activation for long-lasting behavioral and cellular plas-
ticity are well described (for a review, see Thomas and Huganir,
2004). However, inter-trial MAPK activation has only recently
been characterized (Ajay and Bhalla, 2004; Pagani et al., 2009;
Philips et al., 2007, 2013b). For example, we recently reported
that an early phase of activated MAPK translocates to the nu-
cleus, activates the CREB kinase p90rsk, regulates apc/ebp
expression, and is required for two-trial LTM (Philips et al.,
2013b). The functional significance of late phases of MAPK acti-
vation that are required for LTM in Aplysia (J. Shobe et al., 2005,
Soc. Neurosci., abstract) remain to be elucidated, and the rela-
tive contribution of distinct phases of MAPK activation across tri-
als during memory induction remains an open question.
Spatial Dissociation of GF Signaling during Memory
Formation
Our data show that, in addition to a temporal dissociation,
signaling from different GF families is also recruited in spatially
distinct subcellular compartments. Although human recombi-
nant BDNF and TGF-b1 bound to both pre- and post-synaptic
elements within Aplysia co-culture (Figures 3D and 3E), there ap-
pears to be a spatial dissociation of the functional engagement
of GF signaling. Specifically, TrkB signaling is initiated at the
SN-MN synapse, while TGF-br-II signaling is initiated at the SN
somata (Figures 3B and 3C). Previous reports have indicated
the localization of neurotrophin-like ligands and Trk-like recep-
tors in both the SN and MN (Kassabov et al., 2013; Ormond
et al., 2004; Pu et al., 2014). Taken together, these data suggest
that GF signaling via Trk-like receptors may occur both pre-
and post-synaptically. The working model in Figure 8 depicts
Figure 7. Trial 1 TrkB Signaling and Trial 2
TGF-br-II Signaling Are Required for Two-
Trial LTM for Sensitization of the T-SWR
(A) Semi-intact preparation. Two-trial behavioral
training is administered to the training site, and
drug is applied to the isolated CNS chamber in the
experimental paradigms shown above the data
histograms. LTM is measured by stimulating the
test site 15–22 hr after training and measuring the
T-SWR.
(B) Blocking TrkB signaling during trial 1 signifi-
cantly disrupts LTM formation.
(C) Blocking TGF-br-II signaling during trial 2
significantly disrupts LTM formation.
*p < 0.05, **p < 0.01; n = 6.TrkB- and TGF-br-II-like receptors localized to the pre-synaptic
SN to emphasize that the molecular events regulated by
these GF families are occurring in SNs. However, post-synaptic
TrkB-like receptors could also modulate pre-synaptic molecular
events via a trans-synaptic retrograde signaling mechanism.
Interestingly, one such retrograde messenger, nitric oxide, has
been shown to be induced in hippocampal neurons in a TrkB-
dependent manner (Kolarow et al., 2014).
Importantly, the somatic and synaptic compartments include
important circuit components in addition to the SN somata and
SN-MN synapses (Cleary et al., 1995; Marinesco et al., 2004).
Although the SN-MN synapse within the withdrawal circuit is
often sufficient to capture essential features of the plasticity-
underlying behavior in Aplysia, these other components of the
circuit may indeed play important roles in sensitization memory
(Cleary et al., 1995; White et al., 1993). It is important to note
that the post-synaptic MN has an important role in plasticity
and memory in Aplysia (Glanzman, 2008), and determining
whether and how GF signaling is engaged in the MN will be of
considerable interest. Therefore, although our data demonstrate
the importance of synaptic TrkB signaling and somatic TGF-br-II
signaling and the capability for both ligands to bind both pre- and
post-synaptic elements in the withdrawal circuit, the cellular
source of these ligands remains to be elucidated.
One potential advantage for the spatial dissociation of GF
family engagement could be to mediate different functional out-
comes depending on the spatial location of the signaling in the
neuron. For instance, synaptic TrkB signaling could be poised
to quickly modulate local protein synthesis, while somatic
TGFbr-II signaling could have faster or easier access to the
nucleus for transcriptional regulation. Our data indicate that,
despite GF signaling arising from spatially disparate locations
in the neural circuit, both TrkB and TGF-br-II signaling interact
to regulate the same signaling molecule in the same subcellular
compartment: MAPK in SN somata. Importantly, whether the
same pool of MAPK is being regulated in both cases remains
to be clarified. In principle, there could be distinct pools of
MAPK activated by each GF, which could allow each pool of
MAPK to mediate different functional outcomes.
The requirement of synaptic TrkB signaling for subsequent so-
matic events suggests the involvement of a retrogradely trans-
ported intracellular signal (Figure 8A). Interestingly, Jeanneteau
et al. (2010) have provided evidence consistent with this idea.They found that, in primary cortical cultures, stimulation of distal
axons with either BDNF or with depolarizing stimuli was suffi-
cient to induce the transient induction of the gene for a MAPK
phosphatase,mkp-1, an effect that requires MEK activity. These
observations, which are similar to ours, suggest that a synaptic,
TrkB-dependent, retrogradely transported, intracellular signal
resulting in somatic MAPK activation and gene expression may
be a conserved first step in the response to memory-inducing
stimuli. Two reasonable candidates for a possible retrogradely
transported intracellular signal are a signaling endosome and/
or MAPK itself. Considering the first candidate, it is known
that, during development, GFs binding to Trk receptors cause
the internalization of the ligand-receptor complex, giving rise to
a signaling endosome. The tyrosine kinase domain of Trk in
this endosome is exposed to the intracellular environment and
phosphorylates targets as the endosome moves to the soma
(Heerssen and Segal, 2002). Considering the second idea,
MAPK itself is phosphorylated at the synapse and could travel
to the soma, where it translocates into the nucleus to regulate
transcription (Philips et al., 2013b). Indeed, phosphorylated
MAPK has been shown to be transported to the soma via impor-
tin-mediated nuclear transport in response to axonal injury (Perl-
son et al., 2006), and, interestingly, importin-mediated transport
is required for LTF in Aplysia (Thompson et al., 2004).
RNA Regulation during Memory Formation
Another novel feature of our results is the demonstration of a syn-
ergistic interaction between distinct GF families recruited during
memory induction. Specifically, trial 1 TrkB signaling increases
the expression of apc/ebp mRNA, and trial 2 TGF-br-II signaling
prolongs the expression of these mRNAs (Figure 6). These data
highlight two main points: distinct GF families synergistically
promote the expression of ap/cebp, and TGF-br-II signaling
mediates the post-transcriptional regulation of apc/ebpmRNAs.
An important question now will be to determine how TGF-br-II
signaling mediates mRNA regulation.
Gene induction downstream of the transcription factor C/EBP
is a highly conserved requirement for LTM and long-lasting
plasticity (Alberini, 2009). In Aplysia, the homolog of C/EBP has
a short and long isoform and is most similar to mammalian C/
EBPb (Alberini et al., 1994). When a constitutively expressed
transcription factor, ApAF, is phosphorylated by PKA, it dimer-
izes with ApC/EBP and induces transcription. The constitutiveNeuron 86, 1228–1239, June 3, 2015 ª2015 Elsevier Inc. 1235
Figure 8. Working Model of GF Signaling in a Molecular Network
during Two-Trial LTM Formation
(A) Molecular signaling induced by trial 1. (1) Trial 1 induces 5HT release at the
soma and synapse. (2) A TrkB ligand is released at the SN-MN synapse and
binds pre-synaptic TrkB-like receptors. (3) A TrkB-dependent retrogradely
transported, intracellular signal causes early-phase MAPK activation in SN
somata at 45 min. (4) At the same time point, TrkB signaling increases apc/ebp
mRNA expression.
(B) Molecular signaling induced by trial 2. (1) Trial 2 delivered at 45min induces
5HT release at the soma and synapse. (2) A TGF-br-II ligand is released at SN
somata, where it binds somatic TGF-br-II-like receptors, which is responsible
for at least two functional outcomes. (3) 15 min after training, TGF-br-II
signaling interacts synergistically with the TrkB signaling cascade to prolong
apc/ebp mRNA expression established by trial 1. (4) Additionally, TGF-br-II
signaling independently regulates late-phaseMAPK activation in SN somata at
a later time point (1 hr post-training).activation of this complex alone can support LTF in the absence
of CREB-mediated transcription (Bartsch et al., 2000; Lee et al.,
2006). Previous results show that apc/ebp mRNA stabilization
can be bi-directionally regulated by the AU-rich element (ARE)
RNA binding proteins ApAUF1 and ApELAV (Lee et al., 2012;
Yim et al., 2006). ApAUF1 binding to the 30 UTR of apc/ebp
induces the degradation of the transcript, and overexpression
of ApAUF1 inhibits 5HT-induced LTF in SN-MN coculture (Lee
et al., 2012). Conversely, ApELAV binds in the same ARE region,
but, in contrast to ApAUF1, it stabilizes the transcript (Yim et al.,
2006).1236 Neuron 86, 1228–1239, June 3, 2015 ª2015 Elsevier Inc.Interestingly, there is evidence that TGF-b can initiate stabili-
zation of mRNAs via an RNA binding complex (Amara et al.,
1995). For example, in cardiac fibroblasts, TGF-b1 treatment
induced HuR (a member of the ELAV family) translocation from
the nucleus to the cytoplasm, where it bound the ARE region
of the 30UTR in tgfb1 mRNA, therefore stabilizing the mRNA
and increasing protein expression (Bai et al., 2012). These data
suggest the intriguing possibility that trial 2 TGF-br-II signaling
may initiate a cascade that recruits ELAV family RNA binding
proteins to prolong the expression of critical learning-related
genes like c/ebp. Furthermore, other GF ligands could be
induced and stabilized in the same way (including a TGF-b1-
like ligand itself).
MAPK activation may also play a role in mRNA stabilization.
Nerve growth factor (NGF) and epidermal growth factor (EGF)
stimulation of PC12 cells stabilized m4 muscarinic acetylcholine
receptor mRNA in a MEK-dependent (the upstream activator
of MAPK) and protein synthesis-dependent manner (Lee and
Malek, 1998). MAPK activation has also been implicated in the
HuR binding and subsequent stabilization of mRNAs in hepato-
cytes (Yashiro et al., 2013) and non-small-cell lung carcinoma
cells (Yang et al., 2004) and is required for the stabilization of
GF ligand mRNAs in cardiomyoblasts (Miller et al., 2012). Addi-
tionally, ApC/EBP protein has been shown to require MAPK
phosphorylation for its DNA-binding capability in addition to pro-
tecting it from proteasomal degradation (Yamamoto et al., 1999).
Since both prolonged expression of apc/ebp (Figure 5B3) and
latephase MAPK activation (Figure 2A3) is dependent on trial 2
TGF-br-II signaling, it will be important to determine the role of
TGF-br-II-dependent MAPK signaling in the regulation of ApC/
EBP mRNA and protein.
In conclusion, the results in this paper, taken collectively,
emphasize the rich and complex interactions between multiple
GF families, both in parallel and synergistically, during memory
formation. These data therefore support the notion (Kopec and
Carew, 2013) that GFs do not act in isolation but, rather, as a
complex, spatiotemporally regulated molecular network that is
engaged in the service of information storage within a neural
circuit.EXPERIMENTAL PROCEDURES
Ganglion Preparation
Pleural-pedal ganglia were dissected from anesthetized Aplysia californica
(150–250 g, South Coast Bio-Marine). In a 1:1 solution of MgCl2 and artificial
sea water (ASW), the pleural SN cluster and SN-MN neuropil were exposed.
For split-bath analyses, the desheathed ganglia were drawn over a plastic
partition so that the SN somata (somatic compartment) and SN-MN synapses
(synaptic compartment) were on different sides. The partition was sealed with
Vaseline so that the molecular environment of the compartments could be
manipulated independently of one another (Sherff and Carew, 1999). Ganglia
were perfused with ASW for at least 1 hr to clear MgCl2 prior to experi-
mentation. Experimental and contralateral within-animal control ganglia both
received GF chimera/vehicle treatment, while only the experimental ganglia
received wo-trial TNS training.
Training and Drug Incubation for MAPK Analyses
The p9 tail nerve was inserted into a suction electrode, and two trains of
electrical stimulation (1.5 s train: 30 V, 40 Hz, 5 ms pulses, inter-trial interval
(ITI) = 45min) were delivered. Ganglia were blocked with 0.1%BSA 5min prior
to GF chimera (TrkB-Fc or TGF-br-II-Fc, R&D Systems, 5 mg/ml) or vehicle
(0.1% BSA in PBS) incubation to reduce nonspecific binding. The chimeras
are polypeptides containing the extracellular portion of human TrkB or TGF-
br-II and were reconstituted at 100 and 50 mg/mL, respectively, in PBS with
0.1% BSA. Pilot experiments guided by prior use of TrkB receptor bodies in
this system tested a range of concentrations (1–5 mg/ml) and determined
that 5 mg/ml exerted a maximal inhibitory effect on MAPK activation (data
not shown). Therefore, we used a final concentration of 5 mg/ml for all experi-
ments. This is consistent with the final effective dose used in previous studies
in our laboratory (Sharma et al., 2006). The GF requirement was tested during
trial 1 or trial 2 by applying GF chimera/vehicle to the bath (with mixing) 10 min
prior to the target trial (e.g., 10 min prior to trial 1 to block GF signaling during
trial 1). When necessary, the drug was washed out with ASW 5 min prior to the
end of the target time window (e.g., 5 min prior to trial 2). Effective pre-incuba-
tion and washout times were determined in pilot experiments (data not shown;
see the overall strategy in Philips et al., 2013b). For split bath preparations, the
drug was added 20 min prior to the target time window without mixing to limit
perturbation (e.g., 20 min prior to trial 1 to test GF during trial 1). SN somata
were collected either 45 min after trial 1 (early-phase MAPK activation) or
1 hr after training (late-phase MAPK activation) and prepared for western
blot analysis.
Western Blotting
Samples were loaded onto 4%–12% Bis-Tris gels (Novex; Life Technologies)
for electrophoresis and then transferred to nitrocellulose membranes for incu-
bation with primary antibodies (total MAPK [p44/42 MAPK, catalog no. 4696]
and phospho-specific MAPK [phospho p44/42 MAPK, catalog no. 4370; Cell
Signaling Technology]) and secondary antibodies IRDye 800CW and IRDye
680RD, LI-COR Biosciences]). MAPK activation (via its phosphorylation) within
each sample was assessed using the LI-COR Odyssey imaging system. Each
phospho-specific band was normalized to the total MAPK band within the
same sample, and normalized phospho-MAPK in the experimental ganglia
was compared to within-animal control ganglia. Data are displayed as percent
of normalized MAPK activation relative to control.
GF Stimulation and Immunocytochemistry
Pleural SN-L7 abdominal MN co-cultures (at least 5 days in vitro [d.i.v.]; Zhao
et al., 2009) were incubated with human biotinylated TGF-b1 or BDNF for
30 min at 4C (R&D Systems Fluorokine kits, 2:5). Control experiments were
performed in parallel using control protein with equivalent biotinylation
(soybean trypsin inhibitor, provided in R&D Systems kits). Co-cultures
were then incubated with avidin-fluorescein (2:7, R&D Systems) for 30 min at
4C. The co-cultures were fixed (4% paraformaldehyde in 30% sucrose PBS
for 15 min) and mounted with Pro-Long Gold antifade reagent (Life Technolo-
gies). Images were collected using a Leica SP5 and prepared with ImageJ
software.
Training and Drug Incubation for Gene Expression Analyses
Two-trial analog training was delivered (2 s train: 30 V, 40 Hz, 5 ms pulses,
ITI = 45 min), and ganglia were blocked with BSA. The drug was applied
20 min prior to the target trial and, when necessary, was washed out 20 min
prior to the end of the target time window. SN somata were collected at the
experimental time point and prepared for quantitative PCR analysis.
RNA Isolation, cDNA Synthesis, and Quantitative PCR Analysis
RNA was isolated and purified using QIAGEN RNeasy mini kit columns
(QIAGEN). Total RNA was normalized for pairs of experimental and control
ganglia (100 ng), and cDNA was synthesized using Superscript III CellsDirect
cDNA synthesis reagents (Invitrogen, CellsDirect). Quantitative PCR was
performed using a Roche LightCycler 480 and SybrGreen (Roche, 3 min at
95C, 30 cycles of 10 s at 95C, 20 s at 50C, and 30 s at 72C). The following
primers (5 mM) were used: apc/ebp-F 50-caccacctcactcccatctc-30, apc/ebp-R
50-ctgacgtctgcgagactttg-30, apuch-F 50-gaagacgaagccactcaacc-30, apuch-R
50-tgagatggagcctgtgtgtc-30, apkhc1-F 50-aaggaagctgtcaggcagag-30, apkhc1-R
50-gatggctgtaccacctcctc-30, apgapdh-F 50-ctctgagggtgctttgaagg-30, and
apgapdh-R 50-gttgtcgttgagggcaattc-30. The quantity of each gene (measured
by Ct) was normalized to apgapdh within the same sample (DCt), and thennormalized values were compared between experimental and within-animal
control groups (DDCt).Dataaredisplayedas fold induction relative to the control.
Semi-intact Behavioral Preparation
Preparations were prepared as described previously (Sutton et al., 2001).
Briefly, the cerebral and paired pleural-pedal ganglia from anesthetized Aply-
sia (250–400 g, South Coast Bio-Marine) were isolated surgically, leaving p9
and pleural-abdominal innervation to the tail and abdominal ganglia, respec-
tively, intact. The tail and mantle were removed surgically, and the siphon ar-
tery was cannulated with Dow Corning silastic tubing (0.025 inner diameter
[I.D.], Fisher Scientific) and perfused at 5 ml/min, while the tail was perfused
at0.5 ml/min via three 22-gauge needles. The tail and mantle were pinned to
the chamber floor, while the ring ganglia with both pleural-pedal ganglia
desheathed were pinned in an isolated CNS chamber. Both chambers were
perfused continuously with seawater (Instant Ocean, 15C). The p9 and
pleural-abdominal nerves exited the CNS chamber through small slits that
were sealed with Vaseline. Preparations were allowed to recover for at least
2 hr prior to baseline measurements.
Training and Drug Incubation for LTM Analyses
An average of three to four baseline T-SWR measurements were recorded
by stimulating the medial posterior tip of the tail with a water jet (0.4 s, 45
psi, ITI = 15 min, Teledyne Water Pik). There were no significant differences
in the pre-training baseline T-SWRs under any experimental condition
(H = 0.7, df = 3, p = 0.9). The CNS was incubated with BSA, followed by
drug 20 min prior to the target trial, which was washed out 15 min after the
target trial. Two-trial LTM training (100 mA, 1.5 s, ITI = 45 min) was delivered
medially to the anterior portion of the tail through a hand-held electrode.
LTM for sensitization of the T-SWR was assessed by three to four tests
(ITI = 15 min) 15–22 hr after training by an experimenter blind to the experi-
mental condition (GF chimera versus vehicle). The data are displayed as the
duration of T-SWR as a percent of the pre-training baseline.
Statistical Analyses
Because of the non-normality of the data, all data were analyzed using non-
parametric statistics with GraphPad Prism. Within-group analyses were per-
formed using Wilcoxon matched-pairs signed-rank tests. Specifically, MAPK
activation and gene expression in experimental ganglia were compared with
within-animal control ganglia, and the LTM for sensitization of T-SWR is
compared relative to the pre-training baseline T-SWR within the same prepa-
ration. Between-group analyses (chimera versus vehicle) were performed
using Mann-Whitney U tests. When appropriate, Kruskal-Wallis analyses
were used to determine whether there was a difference among the groups,
and significant results were followed by planned Wilcoxon or Mann-Whitney
comparisons. Outliers greater than 2 SDs from themean were excluded (Dixon
and Tukey, 1968), resulting in the removal of ten data points (<4% of all data
points, reported in the text). Data in all figures are depicted as median ±
IQR. Significant within-group comparisons are displayed as asterisks above
the summary data, and significant between-group comparisons are displayed
as asterisks above a bar between the summary data.
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